JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Murray, A.
Right arrow Articles by Perkins, A. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Murray, A.
Right arrow Articles by Perkins, A. C.

Production and Characterization of 188Re-C595 Antibody for Radioimmunotherapy of Transitional Cell Bladder Cancer

Andrea Murray, Matthew S. Simms, David P. Scholfield, Rachel M. Vincent, Graeme Denton, Michael C. Bishop, Michael R. Price and Alan C. Perkins

Department of Medical Physics, Medical School, Queen’s Medical Centre, Nottingham; Department of Urology, City Hospital, Nottingham; and Cancer Research Laboratories, School of Pharmaceutical Sciences, University of Nottingham, Nottingham, United Kingdom



View larger version (16K):

[in a new window]
 
FIGURE 1. Affinity separation of 188Re-C595 antibody complex from high-molecular-weight contaminating material. Washing and elution of hybrid affinity column system were performed as follows: PBS (12 mL), 3 mol/L NaSCN (2 mL), and PBS (11 mL). Absorbance values at 280 nm (dashed line) and activity (solid line) of each fraction are plotted. AU = absorbance units.

 


View larger version (16K):

[in a new window]
 
FIGURE 2. Sephacryl S300 gel filtration analysis of affinity-purified 188Re-C595 antibody complex (solid line) measured as activity in counts per minute (cpm), unlabeled C595 antibody (dashed line) measured as absorbance at 280 nm, and 188Re–sodium perrhenate (dotted line) measured as activity in cpm. AU = absorbance units.

 


View larger version (17K):

[in a new window]
 
FIGURE 3. Stability of the 188Re-C595 antibody complex as measured by ITLC. Untreated 188Re-C595 ({square}) was compared with 188Re-C595 that had 1% BSA ({circ}), 0.2% ascorbic acid ({blacktriangleup}), and both 1% BSA and 0.2% ascorbic acid ({diamondsuit}) added after labeling.

 


View larger version (75K):

[in a new window]
 
FIGURE 4. Tumor localization of 188Re-C595 in ex vivo model. (A) Postwashout gamma-camera image shows area of increased uptake on right-hand side of specimen. (B) Bladder was dissected to reveal area of tissue that had neoplastic appearance corresponding to hot spot on gamma-camera image (A). Presence of transitional cell carcinoma was confirmed by pathologic examination.

 


View larger version (73K):

[in a new window]
 
FIGURE 5. (A) Intravenous pyelogram shows large filling defect on left-hand side of bladder, which was confirmed as G3pT1 transitional cell carcinoma at operation. (B) Gamma-camera image shows localized uptake of 188Re-C595 complex at site of tumor.

 





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2001 by the Society of Nuclear Medicine.